Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21965748 | 0.87 | DDB1 (0.69) | DDB1CRBNKIF11 | |
| SCHEMBL25952669 | 0.85 | DDB1 (0.49) | DDB1CRBNKIF11 | |
| SCHEMBL26328210 | 0.84 | DDB1 (0.54) | DDB1CRBNKIF11 | |
| SCHEMBL25952612 | 0.81 | DDB1 (0.55) | DDB1CRBNKIF11 | |
| SCHEMBL26375308 | 0.81 | DDB1 (0.51) | DDB1CRBNKIF11RXFP1 | |
| SCHEMBL26328760 | 0.81 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL25952615 | 0.79 | DDB1 (0.53) | DDB1CRBNKIF11 | |
| SCHEMBL25666680 | 0.77 | DDB1 (0.48) | DDB1CRBNKIF11 | |
| SCHEMBL25952690 | 0.75 | DDB1 (0.45) | DDB1CRBN | |
| SCHEMBL21965376 | 0.74 | DDB1 (0.69) | DDB1CRBNKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | DDB1 438/4885CRBN 144/4885KIF11 1899/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | DDB1 438/4885CRBN 144/4885KIF11 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.